

Spleen Stiffness Measurement for the Detection of Advanced Fibrosis

NCT07440511

Status RECRUITING
Sponsor Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Enrollment 500 participants

Key Eligibility Criteria

Inclusion (4)

- Age \geq 18 years
- Diagnosis of MASLD according to EASL guidelines
- Presence of cACLD confirmed by histology (fibrosis F3-F4) or assessed non-invasively (LSM \geq 15 kPa), OR suspected cACLD based on non-invasive tests (LSM \geq 8 kPa) that leads to or has led to the indication for liver biopsy according to routine clinical practice
- Signed informed consent for the prospective cohort

Exclusion (9)

- Other etiologies of liver disease, including viral, autoimmune/cholestatic, drug-induced, alcohol-related liver disease (ALD), or use of hepatotoxic drugs (e.g. long-term oral corticosteroids, estrogen-progestin therapy, methotrexate, valproic acid)
- Primary or secondary liver cancer
- Previous hepatic decompensation
- Hematological disorders
- Portal vein thrombosis
- ... and 4 more (see full listing online)

Locations (1 total)

Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy